2.2.2017 Secondary announcement-p.m.
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Neos Therapeutics Symbol: NEOS Price: Last trade $5.80 Description: Re-offer $5.00 Trade Date: 2/3 Shares: 5 million Underwriter(s)Cowen & Co., BMO[…]